MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…
In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login, take a free trial or subscribe in order to continue reading.
{iframe}http://www.thepharmaletter.com/article/medimmune-and-shionogi-sign-license-agreement-for-shionogi-s-preclinical-biologics-in-acute-coronary-syndrome{/iframe}